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Sustained Benefits in Vascular
Function Through Flavanol-Containing
Cocoa in Medicated Diabetic Patients
A Double-Masked, Randomized, Controlled Trial
Jan Balzer, MD,* Tienush Rassaf, MD,* Christian Heiss, MD,* Petra Kleinbongard, PHD,*
Thomas Lauer, MD,* Marc Merx, MD,* Nicole Heussen, PHD,† Heidrun B. Gross, PHD,‡
Carl L. Keen, PHD,‡ Hagen Schroeter, PHD,§ Malte Kelm, MD*
Aachen, Germany; Davis, California; and Rockville, Maryland
Objectives Our goal was to test feasibility and efficacy of a dietary intervention based on daily intake of flavanol-containing
cocoa for improving vascular function of medicated diabetic patients.
Background Even in fully medicated diabetic patients, overall prognosis is unfavorable due to deteriorated cardiovascular
function. Based on epidemiological data, diets rich in flavanols are associated with a reduced cardiovascular risk.
Methods In a feasibility study with 10 diabetic patients, we assessed vascular function as flow-mediated dilation (FMD) of
the brachial artery, plasma levels of flavanol metabolites, and tolerability after an acute, single-dose ingestion of
cocoa, containing increasing concentrations of flavanols (75, 371, and 963 mg). In a subsequent efficacy study,
changes in vascular function in 41 medicated diabetic patients were assessed after a 30-day, thrice-daily dietary
intervention with either flavanol-rich cocoa (321 mg flavanols per dose) or a nutrient-matched control (25 mg
flavanols per dose). Both studies were undertaken in a randomized, double-masked fashion. Primary and sec-
ondary outcome measures included changes in FMD and plasma flavanol metabolites, respectively.
Results A single ingestion of flavanol-containing cocoa was dose-dependently associated with significant acute increases
in circulating flavanols and FMD (at 2 h: from 3.7  0.2% to 5.5  0.4%, p  0.001). A 30-day, thrice-daily con-
sumption of flavanol-containing cocoa increased baseline FMD by 30% (p  0.0001), while acute increases of
FMD upon ingestion of flavanol-containing cocoa continued to be manifest throughout the study. Treatment was
well tolerated without evidence of tachyphylaxia. Endothelium-independent responses, blood pressure, heart
rate, and glycemic control were unaffected.
Conclusions Diets rich in flavanols reverse vascular dysfunction in diabetes, highlighting therapeutic potentials in cardiovas-
cular disease. (J Am Coll Cardiol 2008;51:2141–9) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.01.059r
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lhe prevalence of type 2 diabetes mellitus is rising world-
ide, accompanied by an increasing risk of cardiovascular
isease and mortality (1). Intense pharmacologic treatment
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008, accepted January 21, 2008.egiments are necessary, but often remain inadequate to
revent incidence and complications of type 2 diabetes
ellitus (2). Observational studies have shown that physical
ctivity, weight loss, and diet can prevent diabetes and its
omplications (3). Primary and secondary prevention of type
diabetes and its complications by life style modifications is
ighly desirable.
See page 2150
Diet is a major lifestyle factor that can greatly influence
he incidence and the progression of chronic diseases, such
s cancer, cardiovascular disease, and diabetes (1). Recently,
avanols, a subgroup of plant-derived phytochemicals called
avonoids, have gained increasing attention, as epidemio-
ogical investigations revealed an inverse correlation be-
ween the dietary intake of flavanols and the mortality of
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Endothelial Function and Flavanols in Diabetes June 3, 2008:2141–9cardiovascular disease (4), and
the incidence of diabetes (5). In
the context of human nutrition,
flavanols are found in fruit, veg-
etables, tea, red wine (6), and
especially high concentrations can
be present in cocoa and cocoa
products (7). Dietary interventions
ith flavanol-containing cocoa products in humans indicate
eneficial effects of flavanols on low-density lipoprotein oxida-
ion (8), platelet aggregation (9), insulin sensitivity (10), endo-
helial function (11), and blood pressure (12).
Controlled trials evaluating longer-term effects of flavanol-
ontaining cocoas on endothelial function in diabetic patients
re missing. The aim of this double-masked, randomized,
ontrolled study was to examine the vasculoprotective impact
f daily flavanol-containing cocoa intake in diabetic patients.
ethods
feasibility study was performed as proof-of-concept and
ose-finding, and to assess safety and tolerability. In addition,
he effect size of flow-mediated dilation (FMD) was measured
n order to calculate appropriate sample sizes for subsequent
nvestigations. In a consecutive efficacy study, the effects of daily
avanol-containing cocoa intake on vascular function were
nvestigated. Both studies were double-masked, randomized,
nd controlled for macro- and micro-nutrient content in the
avanol-containing cocoa and its control.
articipants. Volunteers of both genders, between 50 and
0 years of age, with established and stably-treated type 2
iabetes mellitus for at least 5 years were screened. Eligi-
ility was confirmed according to the guidelines of the
merican Diabetes Association (13). Other cardiovascular
isk factors and pre-existing cardiovascular disease did not
reclude from participation in the study. Exclusion criteria
ere congestive heart failure with a cardiac ejection fraction
f 30%, malignancies, chronic kidney disease with a
lomerular filtration rate of 30 ml/min, severe cardiac
rrhythmias, and inflammation (C-reactive protein 5
g/l). All volunteers were either life-long nonsmokers or
eported smoking abstinence of at least 5 years before study
nclusion. Volunteers participating in the feasibility study were
sked to refrain from foods already known to have a high
ontent of flavanols, such as tea, red wine, certain vegetables,
nd cocoa products (6). Participants enrolled for the efficacy
tudy were allowed to continue their normal, daily lifestyle and
ating habits. All volunteers fasted overnight and refrained
rom their prescribed medication for 12 h before and until
ompletion of the studies in the morning on each study day.
tudy design. For the feasibility study, diabetic patients
ere randomized in a double-masked, 3-period cross-over
esign, and consumed either a cocoa drink that provided a
ontrol (75 mg of flavanols), medium (371 mg of flavanols),
r high (963 mg of flavanols) dose of flavanols on 3 different
Abbreviations
and Acronyms
FMD  flow-mediated
dilation
GTN  glycerol trinitrate
NO  nitric oxideccasions. Eligible patients were assigned to the control, medium, and high flavanol dose by permuted block ran-
omization with blocks of length 3 stratified by gender. The
fficacy study was undertaken using a randomized, double-
asked, parallel-group design, and eligible diabetic patients
ere allocated to a treatment group (321 mg of flavanols per
ose; 3 doses per day), or a control group (25 mg of flavanols
er dose; 3 doses per day). Each group ingested a single dose
f either treatment or control thrice daily over a period of 30
ays. Volunteers were assigned to the control or the treat-
ent group using permuted block randomization with
locks of lengths 4 stratified by gender. To conceal alloca-
ions from investigators, instructed staff at an independent
ite, not involved in this investigation, generated and main-
ained the randomization lists.
Study protocols were approved by the institutional review
oards. All volunteers were informed about the study, and
ave written informed consent to be included. Before intake
f the flavanol-containing cocoa, baseline measurements of
MD of the brachial artery, plasma flavanol metabolites,
rterial blood pressure, and heart rate were obtained. For the
easibility study, FMD measurements were repeated at 1, 2,
, 4, and 6 h after ingestion of the cocoa drink (Fig. 1A).
ased on previous reports demonstrating that flavanol
etabolites reach a maximum plasma level around 2 h after
ngestion (14,15), a blood sample was also taken at the 2 h
ime point to determine plasma flavanol concentrations.
tudy days were separated by at least 3 days to avoid
otential carry-over effects. For the efficacy study, measure-
ents of baseline FMD, blood pressure, heart rate, clinical
outine, and plasma flavanol metabolites were obtained on
ay 0 before intake of the first cocoa drink. To assess acute
ffects, the latter measurements were repeated on the same
ay, 2 h after ingestion of the control (25 mg of flavanols)
r the treatment (321 mg of flavanols) cocoa drink. Volun-
eers were then asked to ingest the cocoa drinks thrice daily.
or the evaluation of long-term effects, the same study
rotocol was repeatedly applied on days 8 and 30 (Fig. 1B).
dherence to the study protocol was confirmed by weekly
elephone inquiries, and by collecting the returned empty
ocoa sachets at each follow-up visit.
lavanol-containing test materials. The cocoa drinks were
upplied as dry cocoa beverage mix by Mars Incorporated
Hackettstown, New Jersey). The flavanol-containing cocoa
rinks were made using CocoaPro cocoa powder. All cocoa
rinks were standardized for their flavanol content and profile,
nd closely matched for equal macro-nutrients, micro-
utrients, caloric load, theobromine, and caffeine content
Table 1). All cocoa drinks were similar in taste and supplied in
ndividual, opaque sachets that were labeled with an anony-
ized 3-digit identifier code. All sachets contained 18 g of
ocoa beverage mix, of which 54% (w/w) consisted of nonfat
ilk powder. A sachet either contained 25 mg (control) or 321
g of total flavanols. Total flavanol amounts referenced here
re defined as the sum of all monomeric flavanols and their
ligomeric derivatives (dimers to decamers, i.e., 2 to 10
onomeric subunits). The monomeric flavanol fraction, 18%
(
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June 3, 2008:2141–9 Endothelial Function and Flavanols in Diabetesw/w) of which is ()epicatechin, represents approximately
3% (w/w) of the total flavanol content. For the feasibility
tudy, cocoa drinks were prepared by mixing the cocoa beverage
owder from 3 cocoa drink sachets into 250 ml of distilled
ater. The resulting cocoa drinks contained either 75 mg (3
5 mg), 371 mg (1  321 mg, 2  25 mg), or 963 mg (3 
21 mg) of flavanols. For the efficacy study, participants were
sked to mix the content of 1 cocoa sachet in 250 ml of water
hrice daily, and to drink it along with their usual meals.
utcome measures. The primary outcome measure was
hange of endothelial function, measured as FMD of the
rachial artery, using standard techniques according to the
uidelines of the American College of Cardiology (16).
riefly, the diameter of the brachial artery was measured 1
o 2 cm above the cubital fossa before and after ischemia of
Hemodynamics +             +     +      +     +             +        
FMD +             +     +      +     +             +        
Plasma flavanols +                    +
0 1 2 3 4 5-1 6 h
Timepoints of 
measurements:
Medium Control
Feasibility study
Hemodynamics +  +       +  +                                 +   +
FMD +  +       +  +                                 +   +   
Plasma flavanols +  +       +  +                                 +   +
Timepoints of 
measurements:
Treatment vs Control
80 30 d
0  2 h h 2  0h 2  0
Efficacy study
High
Treatment vs Control
Thrice daily ingestion
Parallel-group design
Singular ingestion
Cross-over design
Cocoa drinks:
Cocoa drinks:
A
B
Figure 1 Study Protocol
(A) Feasibility study: double-masked, randomized study design to test acute
effects (red) of a single ingestion of flavanol-containing cocoa in diabetic
patients, and to assess dosage regimens for long-term studies. Flow-mediated
dilation (FMD) and hemodynamics were measured before and up to 6 h after
consumption of a single cocoa drink available at 3 different flavanol doses
(high: 963 mg of flavanols  red square; medium: 371 mg  red triangle; or
control: 75 mg  red circle). Plasma flavanol metabolites were measured
before and 2 h after cocoa intake. Each cocoa ingestion was separated by at
least 3 days to avoid potential carry-over effects. (B) Efficacy study: double-
masked, randomized, controlled, parallel-group study design to investigate the
sustained effects (green) of regular daily cocoa intake on endothelial function
in diabetic patients. Patients were randomized to receive cocoa containing
either a cumulative dose of 963 mg of flavanols (treatment group: 3  321 mg
daily  green squares) or 75 mg of flavanols (control group: 3  25 mg daily
 green circles). Flow-mediated dilation, hemodynamic parameters, and
plasma flavanol metabolites were measured 1 h before and 2 h after the morn-
ing cocoa drink at study entry (day 0), after 1 week (day 8), and after 1 month
(day 30).he forearm using a 15 MHz transducer (Vivid 7, GE *ealthcare) and an automatic edge-detection software (Bra-
hial Analyzer, Medical Imaging Applications, Iowa City,
owa) yielding a coefficient of variation of 5%. Reactive
yperemia was induced by 5 min of distal lower arm
cclusion. After 60 to 90 s, the diameter was assessed and
MD calculated as relative diameter gain compared with
hat at baseline. Endothelium-independent dilation was
easured 4 min after sublingual application of 400 g
lycerol trinitrate (GTN). Measurements were performed in
he morning after an overnight fasting period in a noise-
rotected room of constant temperature (24°C).
Secondary outcome measures included changes of the concen-
ration of plasma flavanol metabolites at 2 h after ingestion of
ocoa drinks. Free, aglyconic flavanols (epicatechin, catechin), and
heir respective conjugated flavanol metabolites (3=-O-methyl-
picatechin, 4=-O-methyl-epicatechin, 3=-O-methyl-catechin,
=-O-methyl-catechin, epicatechin-5/7-O--D-glucuronide, 3=-
-methyl-epicatechin-5/7-O--D-glucuronide, 4=-O-methyl-
picatechin-5/7-O--D-glucuronide) were extracted from
lasma and analyzed by high-pressure liquid chromatogra-
hy using an fluorescence detector detection system
Hewlett Packard 1100 Series; high-pressure liquid chro-
atography column: Phenomenex Luna C18(2) 150  4.6
m, 3 m) under utilization of chemically authentic stan-
ards as detailed elsewhere (15). Other pre-specified out-
ome measures were changes in blood pressure, plasma
evels of lipids, fasting plasma glucose, and glycated hemo-
lobin. Blood samples were analyzed in a central laboratory.
tatistical analyses. Continuous variables are presented as
ean  standard deviation. Categorical data are presented by
omposition of Cocoa Drinks
Table 1 Composition of Cocoa Drinks
Nutritional Details
Dosage*
Control Medium High
Monomers, mg 21.0 98.6 253.8
Epicatechin 16.8 78.9 203.0
Catechin 4.2 19.7 50.8
Dimers, mg 21.0 74.3 180.9
Trimers-decamers, mg 33.0 198.1 528.3
Theobromine, mg 570.3 575.6 586.2
Caffeine, mg 36.9 35.2 31.8
Sodium, mg 261.0 238.0 192.0
Potassium, g 1,031.4 991.8 912.6
Calcium, mg 405.0 415.6 436.8
Iron, mg 7.8 6.4 3.6
Phosphorus, mg 444.3 459.6 490.2
Magnesium, mg 132.3 137.2 147.0
Zinc, mg 2.7 2.7 147.0
Copper, mg 0.6 0.6 0.6
Cholesterol, mg 0.0 0.0 0.0
Sugars, g 15.0 15.0 15.0
Carbohydrates, g 27.0 27.0 27.0
Protein, g 15.0 15.0 15.0
Total fat, g 4.5 4.0 3.0
Calories, kcal 171.0 167.0 159.0Cumulative daily intake.
f
v
p
l
t
H
t
g
a
w
a
t
i
t
8
a
u
c
t
l
S
(
R
S
r
f
2144 Balzer et al. JACC Vol. 51, No. 22, 2008
Endothelial Function and Flavanols in Diabetes June 3, 2008:2141–9requencies and percentages. A repeated measures analysis of
ariance was applied to compare mean FMD values between
atient groups. Model assumptions were checked via Mauch-
y’s test of sphericity. If the within-subject factors failed to meet
he assumption of sphericity, we adjusted the results by
uynh-Feldt correction factor. Additionally post-hoc pairwise
tests of baseline values between day 0, 8, and 30 in each
roup, between the control and treatment groups on each day,
nd between 0 h and 2 h on each day in the treatment group
ere performed. Because of the exploratory nature of the
nalyses, no adjustment was made to account for multiple
esting. Sample-size calculations, based on the feasibility study
ndicated that 20 patients in each group needed to be enrolled
o detect an effect size of 0.9 with a 5% 2-sided significance and
Figure 2 Enrollment and Randomization
This double-masked, randomized trial, designed to study the effects of a dietary in
a consecutive efficacy study. Ten patients were randomized into the feasibility stu
ment group, receiving a cumulative daily dose of flavanols of 75 mg (control group0% power. Demographic, anthropometric, hemodynamic,
nd clinical chemistry parameters were compared with the
npaired t test in case of continuous data; in the case of
ategorical data, the Fisher exact test was performed. Applied
ests were 2-sided, and resulting p values less than an alpha
evel of 0.05 were considered to indicate statistical significance.
tatistical analyses were performed using SAS Release 9.1.3
SAS Institute Inc., Cary, North Carolina).
esults
tudy population. Information on volunteer enrollment,
andomization, inclusion and exclusion, as well as reasons
or the latter are detailed in Figure 2.
tion on vascular function in diabetic patients, consisted of a feasibility study and
the efficacy study, 44 patients were assigned to either the control or the treat-
963 mg (treatment group), respectively.terven
dy. For
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June 3, 2008:2141–9 Endothelial Function and Flavanols in Diabetesaseline characteristics. The clinical baseline characteris-
ics of both the study populations assigned to the feasibility
tudy and the efficacy study are shown in Table 2. At the
eginning of the efficacy study, demographic and anthropo-
etric parameters were similar in the control and the
reatment groups.
rimary outcome measure. Before intervention, the mean
MD for the feasibility study population was 3.8  0.3%.
he consumption of flavanol-containing cocoa dose-
ependently increased FMD as shown in Figure 3. Inges-
ion of the control drink, containing 75 mg of flavanols, did
ot cause an increase in FMD. When ingesting the highest
avanol dose (963 mg), the average FMD response in-
reased to 5.5 0.4% (p 0.001) at 2 h after ingestion. On
n individual basis, all participants exhibited statistically
ignificant increases in FMD and plasma flavanol concen-
rations (Fig. 4). Flow-mediated dilation responses returned
lmost to baseline values at 6 h after cocoa ingestion. The
alf-life period of biological effects as measured by FMD
as reached at around 4 h after consumption of the cocoa
rinks containing 371 or 963 mg of flavanols, respectively.
ndothelium-independent vasodilation after sublingual ap-
lication of GTN was similar between study days, and the
ifferent dietary interventions (75 mg: 8.4  0.4%; 371 mg:
.3  0.4%; 963 mg: 8.1  0.3%; p  NS).
Regarding the efficacy study, baseline FMD values (base-
ine: t  0, after overnight fast, before cocoa consumption)
t the start of the intervention (day 0) were not statistically
ifferent when comparing the control with the treatment
roup (3.3  1.2% vs. 3.3  1.1%, p  NS). The daily
onsumption of flavanol-containing cocoa by patients as-
igned to the treatment group resulted in continual baseline
MD increases. Baseline FMD increased from 3.3  1.1%
n day 0 to 4.1  1.1% (p  0.001) on day 8, and to 4.3 
Clinical Baseline Characteristics of the Study P
Table 2 Clinical Baseline Characteristics of
Feasibility Study
(n  10)
Age, yrs 64.7 9.9
Gender, F/M 2/8
Weight, kg 84.9 5.4
BMI, kg/m2 27.8 3.6
Diabetes mellitus, n (%) 10 (100)
History of CAD, n (%) 10 (100)
History of smoking, n (%) 6 (60)
History of hypertension, n (%) 9 (90)
History of dyslipidemia, n (%) 9 (90)
Antiplatelet therapy, n (%) 10 (100)
ACE inhibitor therapy, n (%) 8 (80)
Statin therapy, n (%) 9 (90)
Beta-blocker therapy, n (%) 9 (90)
Oral antidiabetic therapy, n (%) 8 (80)
Insulin therapy, n (%) 2 (20)
ACE  angiotensin-converting enzyme; BMI  body mass index; CAD.2% (p  0.0001) on day 30. The acute effects on FMDt  2 h after cocoa ingestion) in the treatment group were
f similar effect size at study entry (3.3  1.1% to 4.8 
.4%, p  0.0001), after 8 (4.1  1.1% to 5.7  1.6%, p 
.0001), and 30 days (4.3  1.2% to 5.8  1.6%, p 
.0001) of regular cocoa intake. These findings indicate that
esensitization and tachyphylaxia did not occur. While a
omposite maximum increase in FMD, established by a
ombination of chronic and “acute-on-chronic” effects, was
0 1 2 3 4 5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
#
#
* *
*
* *
F
M
D
 (
%
)
Hours (h)
*
-1 6
Cocoa
Figure 3 Time Course of Acute Changes in FMD
Upon Ingestion of Flavanol-Containing Cocoa
For a detailed protocol of the feasibility study, refer to Figure 1A. Baseline val-
ues (black) for flow-mediated dilation (FMD) were similar in all groups at study
entry. After ingestion of the cocoa drinks, containing either a medium (371 mg;
red triangles) or a high (963 mg; red squares) dose of flavanols, FMD
increased significantly, while the ingestion of the control drink (75 mg of fla-
vanols; red circles) had no effect. Data are given as mean  standard devia-
tion. *Indicates significant differences in FMD compared with that seen in
baseline within each group, p  0.05; #Indicates significant differences in
FMD between the control and the high-flavanol dose, p  0.05.
tion
tudy Population
Efficacy Study (n  41)
p Value
Treatment Group
(n  21)
Control Group
(n  20)
63.1 8.3 64.4 8.6 0.6222
13/8 16/4 0.3054
91.8 13.2 92.5 18.9 0.8929
32.1 5.1 31.1 5.1 0.4928
21 (100) 20 (100) 1.0000
15 (71.4) 16 (80) 0.7186
17 (81) 16 (80) 1.0000
19 (90.5) 19 (95) 1.0000
20 (95.2) 16 (80) 0.1836
17 (81) 19 (95) 0.3433
14 (66.7) 10 (50) 0.3499
16 (76.2) 16 (80) 1.0000
15 (71.4) 16 (80) 0.7186
16 (76.2) 15 (75) 1.0000
5 (23.8) 5 (25) 1.0000
nary artery disease.opula
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Endothelial Function and Flavanols in Diabetes June 3, 2008:2141–9ighest at day 30 of the investigation, an ablation of the
ffect size of the composite maximum FMD increase may
ave already taken place onwards of study day 8 (Fig. 5). No
tatistically significant changes over time, and in between
reatment (8.5  2.3% to 9.1  2.9%, p  NS) and control
roups (8.2  2.2% to 7.9  2.4%, p  NS) were observed
onsidering endothelium-independent effects, as assessed
fter sublingual administration of GTN.
econdary outcome measures. In the feasibility study,
ose-dependent increases in FMD after ingestion of the
edium and the high flavanol dose were accompanied by
ncreases in plasma flavanol metabolite levels. The sum of
glyconic flavanols and their respective conjugated flavanol
etabolites in plasma increased dose-dependently within
h from 509  69 nmol/l to 1,038  95 nmol/l when
ngesting 371 mg of flavanols (p  0.05), and from 463 
3 nmol/l to 1,427  80 nmol/l when a 963-mg flavanol
ose was given (p  0.01). The consumption of the control
ocoa drink (75 mg of flavanols) did not result in a
tatistically significant increase in flavanol plasma levels
472  54 nmol/l to 666  72 nmol/l, p  NS).
Regarding the efficacy study, fasting plasma levels of
avanol metabolites in this diet-unrestricted population
ncreased from 1,473  671 nmol/l on day 0 before regular
ntake of flavanol-rich cocoa to values of 2,152  1,222
mol/l on day 8 (p  0.01) and 2,178  995 nmol/l on day
0 (p  0.01). No significant changes in plasma flavanol
Figure 4 Total Plasma Flavanol Metabolites and FMD
Two hours after the consumption of a cocoa drink containing 963 mg of fla-
vanols at study entry (black squares), every study participant exhibited an
increase in flow-mediated dilation (FMD) and in plasma flavanol metabolites
levels, demonstrating acute effects (red squares), and supporting the conjec-
ture that a daily intake of a cumulative dose of 963 mg of flavanols may be
sufficient to induce a sustained improvement in vascular function over time.etabolites were observed in the control group (day 0:,485  1,062 nmol/l; day 8: 1,287  846 nmol/l; day 30:
,501  1,299 nmol/l, p  NS).
For detailed analysis of laboratory, anthropometric, and
emodynamic parameters please refer to Table 3. Serum
alues of electrolytes (sodium, potassium, calcium, chloride,
hosphate, iron, magnesium, zinc) did not change through-
ut the entire study. No side effects such as headaches,
izziness, skin exanthems, altered bowel habits, bloating,
ausea, vomiting, diarrhea, or cardiac adverse events,
uch as worsening of Canadian Cardiovascular Society or
ew York Heart Association functional class, myocardial
nfarction, need for percutaneous coronary intervention
nd bypass surgery were observed during the entire duration of
he trial.
iscussion
ajor findings. The major findings of this randomized
rial are: 1) flavanols present in cocoa are absorbed in a
ose-dependent fashion in diabetic patients; 2) regular daily
ntake of flavanol-containing cocoa reverses vascular dys-
unction in medicated diabetic patients; 3) vasodilation
pon GTN is unaffected by flavanol consumption, indicat-
ng the involvement of endothelium-dependent processes;
nd 4) intake of flavanol-containing cocoa was well toler-
ted without influencing metabolic profile or hemodynamic
arameters.
cute effects of flavanols in diabetic patients. Diabetic
ubjects may exhibit alterations of flavanol absorption due
0 8 30
F
M
D
 (
%
)
Time (d)
3
4
5
6
*
*
*
*
*
#
#
Treatment
Treatment
Treatment
Control
Control
Control
Figure 5 Acute and Sustained Effects of Flavanol-Containing
Cocoa
For a detailed study protocol of the efficacy study refer to Figure 1B. At study
entry (black), baseline values for flow-mediated dilation (FMD) were similar in
both groups. In the treatment group (squares), FMD was significantly aug-
mented over time. On top of sustained FMD increases (green), acute improve-
ments (red) were observed at 2 h after ingestion of flavanol-containing cocoa.
No significant changes could be observed in the control group (circles). Data
are given as mean  standard deviation. *Indicates significant differences in
FMD compared with baseline differences within each group, p  0.001; #Indi-
cates significant differences in FMD between the control group and the treat-
ment group, p  0.05.
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June 3, 2008:2141–9 Endothelial Function and Flavanols in Diabeteso diabetic autonomic neuropathy in different segments
f the gastrointestinal tract, such as esophagus and
tomach dysmotility, delayed transit, and bacterial over-
rowth (17). We observed the absorption of flavanols in
iabetic patients, accompanied by increases in plasma
avanol metabolites, leading to a dose-dependent im-
rovement of endothelial function, corroborating our
ndings from previous studies in nondiabetic populations
14,15). A single-dose intake of flavanol-containing co-
oa improved endothelial function accompanied by in-
reases in plasma flavanol metabolites.
ustained effects of flavanol intake in diabetic patients. Thus
ar, other investigations have not examined the effects of
avanol-containing cocoa on endothelial function in a
iabetic population using materials standardized with regard
o their flavanol content, and fully matched regarding their
ontent of macro-nutrients, and micro-nutrients, caffeine,
heobromine, and caloric load. In this trial, baseline FMD
alues, as assessed in a medicated diabetic patient popula-
ion, indicate that endothelial function is severely impaired.
n our laboratory, reference values for FMD are 5.2  0.5%
n an age-matched, nonsmoking control group without
oronary artery disease, hypertension, diabetes, or hyper-
holesterolemia (18). Interestingly, after a 30-day dietary
ntervention, the composite maximum increase in FMD
the combination of chronic and acute effects) was 5.8 
.6% on day 30, indicating a reversal of endothelial dys-
unction. Most notably, the degree of reversion of endothe-
ial dysfunction was comparable to the reported degree of
MD improvement observed after intermediate- or long-
atient Characteristics of Treatment and Control Groups in the Effi
Table 3 Patient Characteristics of Treatment and Control Grou
Treatment Group (n  21)
Day 0 Day 30
Weight, kg 91.8 13.2 91.2 16.
BMI, kg/m2 32.1 5.0 32.1 5.0
Waist circumference, cm 107.8 9.0 107.6 8.6
MAP, mm Hg 101.0 7.8 101.9 6.9
Heart rate, beats/min 65.0 12.0 62.0 11.
Baseline diameter A. brachialis, mm 4.8 0.5 4.8 0.5
FMD A. brachialis, % 3.3 1.1 4.3 1.2
GTN A. brachialis, % 8.5 2.3 9.1 2.9
Creatinine, mg/dl 0.8 0.1 0.9 0.1
Urea, mg/dl 32.6 7.9 34.9 7.3
CRP, mg/l 3.1 4.5 2.8 3.0
Cholesterol, mg/dl 167.6 33.0 161.3 32.
HDL, mg/dl 47.0 8.7 47.0 9.3
LDL, mg/dl 108.6 31.9 100.1 27.
Triglycerides, mg/dl 151.9 47.4 145.3 45.
Glucose, mg/dl 148.1 33.8 153.4 30.
HbA1c, % 7.0 0.9 6.9 0.9
Plasma flavanol metabolites, nmol/l 1,473.2 670.9 2,177.7 995
MI body mass index; CRP C-reactive protein; FMD flow-mediated dilation; GTN glycerol tr
AP  mean arterial pressure.erm interventions in diabetic patients using controlled axercise (19), or the administration of statins inhibitors (20),
ngiotensin-converting enzyme inhibitors (21), pioglitazone
22), and insulin (23). Assuming that improvement of
ndothelial dysfunction is associated with a better cardio-
ascular prognosis (24), the regular intake of flavanol-
ontaining cocoa should produce similar effects.
otential mechanisms. It is important to comment on the
aily amounts of flavanols that may need to be ingested to
bserve the positive vascular effect obtained in the current
eport. In an early epidemiologic study by Hertog et al. (4),
t was inferred that the daily intake of 30 mg of flavonoids
as sufficient to confer considerable vascular protection.
owever, these estimates were based on an analysis of a
imited number of foods. More recently, Mink et al. (25)
ave estimated that in the U.S. daily intakes of flavanols are
n the order of 20 to 100 mg, respectively (25); thus, the
mounts of flavonoids used in this study significantly aug-
ent the typical diet.
Mechanisms contributing to the biological effects of
avanols include the modulation of cell signalling path-
ays and gene expression (26), inflammation (27), plate-
et aggregation (9), and nitric oxide (NO) homeostasis
28). The precise molecular mechanism by which fla-
anols improve endothelial function in diabetic patients
as not determined in this study. However, our findings
o provide some insights. Endothelial function as mea-
ured by FMD is commonly used as a clinical readout of
ndothelial NO synthesis. Flow-mediated dilation of the
rachial artery is almost entirely NO synthase-dependent
29), correlates with endothelial function of most conduit
Study at Study Entry and at the End of the Study
the Efficacy Study at Study Entry and at the End of the Study
p Value
Control Group (n  20)
p ValueDay 0 Day 30
0.6644 92.5 18.9 93.0 19.5 0.4799
0.7907 31.1 5.1 31.2 4.9 0.1306
0.1602 108.2 16.2 108.7 16.3 0.3952
0.4741 101.3 7.1 101.3 7.3 0.9791
0.8048 65.9 8.3 64.4 11.4 0.6845
0.9304 5.1 0.7 5.1 0.7 0.7316
0.0001 3.3 1.2 3.4 1.1 0.4226
0.4300 8.2 2.2 7.9 2.4 0.6988
0.0140 0.9 0.3 1.0 0.3 0.1306
0.0854 39.2 8.0 40.8 9.1 0.4799
0.7907 6.8 8.8 5.4 6.9 0.3953
0.1062 166.7 38.6 176.5 35.8 0.0578
1.0000 52.1 14.3 55.5 13.3 0.0998
0.0063 103.0 38.5 107.4 34.3 0.3706
0.5077 148.6 85.4 162.1 84.3 0.0629
0.4437 146.8 45.5 144.8 48.0 0.7833
0.0480 7.5 1.2 7.3 1.1 0.0038
0.0027 1,485.0 1,062.0 1,501.0 1,299.4 0.9263
; HbA1c glycosylated hemoglobin; HDL high-density lipoprotein; LDL low-density lipoprotein;cacy
ps in
4
6
6
3
5
9
.1
initraterteries, and can, therefore, be used as a surrogate for
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Endothelial Function and Flavanols in Diabetes June 3, 2008:2141–9ystemic NO synthesis. An increased NO synthase activ-
ty in endothelial cells after treatment with red wine
olyphenols has been demonstrated in vitro (28). In
iabetic subjects, recurrent and prolonged hyperglycemia
educes NO bioavailability, attenuating endothelium-
ependent vasodilation and leading to severe endothelial
ysfunction (30). The consumption of flavanol-containing
ocoa increased peripheral vasodilation in healthy subjects, and
he administration of L-NG-monomethyl arginine, a compet-
tive NO synthase inhibitor, significantly diminished the
ncrease in blood flow, suggesting NO-dependent effects
31). We could demonstrate similar results in a former study
nvolving smokers (14). This concept is further supported by
he findings presented here, demonstrating that there was
o improvement in endothelium-independent vasodilation
fter administration of GTN, and indicating endothelium-
ependent increases of NO bioavailability. The acute ben-
fits of consuming flavanol-containing cocoa on FMD were
n the same range at study entry, after 8 days, and after 30
ays, ruling out desensitization and tachyphylaxia.
linical implications. Impaired endothelial function is a
ey factor for the development of atherosclerosis and its
omplications in diabetic patients, and has been shown to be
n independent predictor of cardiovascular outcomes in
ubjects with cardiovascular risk factors or established car-
iovascular disease (32). Our study clearly establishes im-
rovements of endothelial function after regular consump-
ion of flavanol-containing cocoa in patients with type 2
iabetes, highlighting the potential of flavanol-containing
iets, and underscoring the potential health care benefit for
educing the risk of cardiovascular events in diabetic
atients.
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